320 related articles for article (PubMed ID: 20639499)
1. Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.
Dudgeon DD; Shinde S; Hua Y; Shun TY; Lazo JS; Strock CJ; Giuliano KA; Taylor DL; Johnston PA; Johnston PA
J Biomol Screen; 2010 Aug; 15(7):766-82. PubMed ID: 20639499
[TBL] [Abstract][Full Text] [Related]
2. Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.
Dudgeon DD; Shinde SN; Shun TY; Lazo JS; Strock CJ; Giuliano KA; Taylor DL; Johnston PA; Johnston PA
Assay Drug Dev Technol; 2010 Aug; 8(4):437-58. PubMed ID: 20662736
[TBL] [Abstract][Full Text] [Related]
3. A cell-based high-throughput assay for the screening of small-molecule inhibitors of p53-MDM2 interaction.
Li J; Zhang S; Gao L; Chen Y; Xie X
J Biomol Screen; 2011 Apr; 16(4):450-6. PubMed ID: 21471462
[TBL] [Abstract][Full Text] [Related]
4. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.
Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
[TBL] [Abstract][Full Text] [Related]
5. High content screening biosensor assay to identify disruptors of p53-hDM2 protein-protein interactions.
Hua Y; Strock CJ; Johnston PA
Methods Mol Biol; 2015; 1278():555-65. PubMed ID: 25859976
[TBL] [Abstract][Full Text] [Related]
6. A fluorescent-based high-throughput screening assay for small molecules that inhibit the interaction of MdmX with p53.
Tsuganezawa K; Nakagawa Y; Kato M; Taruya S; Takahashi F; Endoh M; Utata R; Mori M; Ogawa N; Honma T; Yokoyama S; Hashizume Y; Aoki M; Kasai T; Kigawa T; Kojima H; Okabe T; Nagano T; Tanaka A
J Biomol Screen; 2013 Feb; 18(2):191-8. PubMed ID: 22989451
[TBL] [Abstract][Full Text] [Related]
7. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
8. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.
Koblish HK; Zhao S; Franks CF; Donatelli RR; Tominovich RM; LaFrance LV; Leonard KA; Gushue JM; Parks DJ; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Cummings MD; Grasberger BL; Johnson DL; Lu T; Molloy CJ; Maroney AC
Mol Cancer Ther; 2006 Jan; 5(1):160-9. PubMed ID: 16432175
[TBL] [Abstract][Full Text] [Related]
9. The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4.
Yurlova L; Derks M; Buchfellner A; Hickson I; Janssen M; Morrison D; Stansfield I; Brown CJ; Ghadessy FJ; Lane DP; Rothbauer U; Zolghadr K; Krausz E
J Biomol Screen; 2014 Apr; 19(4):516-25. PubMed ID: 24476585
[TBL] [Abstract][Full Text] [Related]
10. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW
Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668
[TBL] [Abstract][Full Text] [Related]
11. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
[TBL] [Abstract][Full Text] [Related]
12. A simple cell-based HTS assay system to screen for inhibitors of p53-Hdm2 protein-protein interactions.
Lundholt BK; Heydorn A; Bjørn SP; Praestegaard M
Assay Drug Dev Technol; 2006 Dec; 4(6):679-88. PubMed ID: 17199506
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
Patel S; Player MR
Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
[TBL] [Abstract][Full Text] [Related]
14. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of the hdm2-p53 interaction.
Böttger A; Böttger V; Garcia-Echeverria C; Chène P; Hochkeppel HK; Sampson W; Ang K; Howard SF; Picksley SM; Lane DP
J Mol Biol; 1997 Jun; 269(5):744-56. PubMed ID: 9223638
[TBL] [Abstract][Full Text] [Related]
16. Rapid screening of protein-protein interaction inhibitors using the protease exclusion assay.
Nirantar SR; Li X; Siau JW; Ghadessy FJ
Biosens Bioelectron; 2014 Jun; 56():250-7. PubMed ID: 24508816
[TBL] [Abstract][Full Text] [Related]
17. Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity.
Leonard K; Marugan JJ; Raboisson P; Calvo R; Gushue JM; Koblish HK; Lattanze J; Zhao S; Cummings MD; Player MR; Maroney AC; Lu T
Bioorg Med Chem Lett; 2006 Jul; 16(13):3463-8. PubMed ID: 16647257
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR
Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275
[TBL] [Abstract][Full Text] [Related]
19. Using BRET to study chemical compound-induced disruptions of the p53-HDM2 interactions in live cells.
Mazars A; Fåhraeus R
Biotechnol J; 2010 Apr; 5(4):377-84. PubMed ID: 20235143
[TBL] [Abstract][Full Text] [Related]
20. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
